Experimental drug cocktail targets tough childhood cancers in adults

NCT ID NCT01858168

Completed Disease control Sponsor: Massachusetts General Hospital Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested a combination of two drugs, olaparib and temozolomide (with or without irinotecan), in 49 adults with Ewing sarcoma or rhabdomyosarcoma that had come back or spread after standard chemotherapy. The main goal was to find the safest dose and see if the combo could shrink tumors. The drugs work by blocking cancer cells' ability to repair their DNA, making them more likely to die. This was an early-phase trial focused on safety, not a cure.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for EWING SARCOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Ewing sarcoma rhabdomyosarcoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

EWING SARCOMA RHABDOMYOSARCOMA

Contacts and locations

Locations

Boston Children's Hospital

Boston, Massachusetts, 02115, United States
Brigham and Women's Hospital

Boston, Massachusetts, 02215, United States
Dana-Farber Cancer Institute

Boston, Massachusetts, 02215, United States
Massachusetts General Hospital

Boston, Massachusetts, 02114, United States
St. Jude's Children's Research Hospital

Memphis, Tennessee, 38105, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.